Announcements Trials
Browse Landscape

Phase

Phase 1 84Phase 2 73Phase 3 53Phase 1/2 41Phase 4 12Phase NA 6Phase 2/3 5Phase EARLY_PHASE1 1

Status

Recruiting 2Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 16INDUSTRY 5NIH 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 81Thoracic 49Genitourinary 30Breast 28Other hematologic neoplasm 27Lymphoid 23Gynecologic 20Head & Neck 17Dermatologic 13Myeloid 12Sarcoma 10CNS 10Plasma cell 7Tumor-Agnostic 5Endocrine 5Other solid neoplasm 4Other 2NET 2Classical hematology 2

Conditions

Thyroid Neoplasms 1Thyroid Carcinoma, Anaplastic 1Neuroendocrine Tumors 1Neoplasm Metastasis 1Gastroenteropancreatic Neuroendocrine Tumors 1Differentiated Thyroid Cancer 1Advanced Neuroendocrine Neoplasm 1Adenoma, Islet Cell 1

Interventions

Everolimus 2lutetium Lu 177 dotatate 1fosbretabulin 1combretastatin 1anlotinib 1Sirolimus 1Paclitaxel 1Injections 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2/3 × INDUSTRY × Endocrine × Clear all
NCT07165886 2026-04-24

Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Phase 2/3 Recruiting
298 enrolled
EndocrineGastrointestinalNET

Gastroenteropancreatic Neuroendocrine Tumors

NCT06943755 2026-04-17

STELLAR-311

Exelixis

Phase 2/3 Recruiting
440 enrolled
EndocrineNET

Adenoma, Islet Cell, Neoplasm Metastasis, Neuroendocrine Tumors

NCT06398444 2025-09-05

A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms

Sinotau Pharmaceutical Group

Phase 2/3 Active not recruiting
74 enrolled
Endocrine

Advanced Neuroendocrine Neoplasm

NCT02586337 2019-05-21

Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2/3 Unknown
113 enrolled
EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT00507429 2014-06-09

FACT

Mateon Therapeutics

Phase 2/3 Terminated
80 enrolled 10 charts
EndocrineHead & Neck

Thyroid Neoplasms, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡